Market Overview

UPDATE: Stifel Nicolaus Initiates Edwards Lifesciences at Buy on Growth Outlook

Share:
Related EW
Goldman's New Pair Trade Opportunity
Earnings Scheduled For July 28, 2015
Mitral Valve Space Heats Up With Abbott Deals (Seeking Alpha)

Stifel Nicolaus initiated coverage on Edwards Lifesciences (NYSE: EW) with a Buy rating and a $113 price target.

Stifel Nicolaus noted, "We are initiating coverage of Edwards Lifesciences Corp. (EW) shares with a Buy rating and a $113 12-month target price. Over time, we think that Edwards' current market leading TAVR share (approximately 64% WW), its healthy new product pipeline, and the move into new geographies (e.g.Japan) will substantially expand the company's profitability and drive sustained above-industry-average growth through mid-decade. As the Transcatheter Valve Replacement market evolves further in years ahead, we believe Edwards is poised to benefit, driving significant top-line growth and operating leverage."

Edwards Lifesciences closed at $85.74 on Monday.

Latest Ratings for EW

DateFirmActionFromTo
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015RBC CapitalUpgradesSector PerformOutperform

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (EW)

Get Benzinga's Newsletters